Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults

BACKGROUND: The 2026 American College of Cardiology/American Heart Association dyslipidemia guideline replaces the pooled cohort equations with the atherosclerotic cardiovascular disease component of the Predicting Risk of Cardiovascular Disease Events equations for primary prevention risk estimation and modifies lipid-lowering therapy (LLT) eligibility by lowering the risk-based treatment threshold and expanding diabetes and chronic kidney disease criteria. The population-level impact of this transition is uncertain. METHODS: We analyzed National Health and Nutrition Examination Survey 2021 to 2023 participants aged 40 to 75 years without self-reported atherosclerotic cardiovascular disease and with available low-density lipoprotein cholesterol. Survey weights were used to generate national estimates. Guideline-supported LLT eligibility was assessed under the 2018 pooled cohort equations-based American College of Cardiology/American Heart Association cholesterol framework and the 2026 Predicting Risk of Cardiovascular Disease Events-based American College of Cardiology/American Heart Association dyslipidemia framework. Current LLT use was assessed among guideline-supported adults. RESULTS: The analytic sample included 1662 participants, representing 115.05 million US adults. LLT was supported for 42.82 million adults under the 2018 framework and 42.17 million under the 2026 framework, a net decrease of 0.65 million. Reclassification was substantial: 37.42 million remained supported, 5.40 million lost support, 4.75 million newly gained support, and 67.48 million remained unsupported. Among supported adults, current LLT use was 39.4% under the 2018 framework and 40.5% under the 2026 framework. CONCLUSIONS: Transition to the 2026 Predicting Risk of Cardiovascular Disease Events-based framework produced little net change in LLT eligibility but meaningfully changed who was supported for therapy. Persistent undertreatment remains a major implementation gap.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-11-12
DOI
https://doi.org/10.1161/jaha.126.053443
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults

Sangho Hyun, Joel Fernandez, Padideh Daneii, Jeffrey L. Williams et al.
Journal of the American Heart Association
Lipoproteins and Cardiovascular Health
article

Population Impact of the 2026 American College of Cardiology/American Heart Association Dyslipidemia Guideline on Lipid‐Lowering Therapy Eligibility Among US Adults

Sangho Hyun, Joel Fernandez, Padideh Daneii, Jeffrey L. Williams, Satyajeet Singh, Ckh Sze
article en

Abstract

BACKGROUND: The 2026 American College of Cardiology/American Heart Association dyslipidemia guideline replaces the pooled cohort equations with the atherosclerotic cardiovascular disease component of the Predicting Risk of Cardiovascular Disease Events equations for primary prevention risk estimation and modifies lipid-lowering therapy (LLT) eligibility by lowering the risk-based treatment threshold and expanding diabetes and chronic kidney disease criteria. The population-level impact of this transition is uncertain. METHODS: We analyzed National Health and Nutrition Examination Survey 2021 to 2023 participants aged 40 to 75 years without self-reported atherosclerotic cardiovascular disease and with available low-density lipoprotein cholesterol. Survey weights were used to generate national estimates. Guideline-supported LLT eligibility was assessed under the 2018 pooled cohort equations-based American College of Cardiology/American Heart Association cholesterol framework and the 2026 Predicting Risk of Cardiovascular Disease Events-based American College of Cardiology/American Heart Association dyslipidemia framework. Current LLT use was assessed among guideline-supported adults. RESULTS: The analytic sample included 1662 participants, representing 115.05 million US adults. LLT was supported for 42.82 million adults under the 2018 framework and 42.17 million under the 2026 framework, a net decrease of 0.65 million. Reclassification was substantial: 37.42 million remained supported, 5.40 million lost support, 4.75 million newly gained support, and 67.48 million remained unsupported. Among supported adults, current LLT use was 39.4% under the 2018 framework and 40.5% under the 2026 framework. CONCLUSIONS: Transition to the 2026 Predicting Risk of Cardiovascular Disease Events-based framework produced little net change in LLT eligibility but meaningfully changed who was supported for therapy. Persistent undertreatment remains a major implementation gap.

Journal of the American Heart Association
Lakeland Regional Medical Center (US)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon